Home » P&G TO MARKET NOVARTIS BLADDER DRUG IN U.S.
P&G TO MARKET NOVARTIS BLADDER DRUG IN U.S.
July 7, 2005
Consumer products maker Procter & Gamble has signed an agreement with Novartis AG to market the Swiss drugmaker's Enablex overactive bladder drug in the United States, Novartis said in a statement on Wednesday. Novartis will continue to record revenues for Enablex, approved by the U.S. Food and Drug Administration as a treatment for overactive bladder, and will pay royalties to P&G's Pharmaceuticals unit based on the product's performance.
Reuters (http://reuters.com/news/newsArticleSearch.aspx?storyID=161570%2B06-Jul-2005%2BRTRS&srch=Procter%2B)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct